These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22072397)

  • 1. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures.
    Donnelly E; Meredith DS; Nguyen JT; Gladnick BP; Rebolledo BJ; Shaffer AD; Lorich DG; Lane JM; Boskey AL
    J Bone Miner Res; 2012 Mar; 27(3):672-8. PubMed ID: 22072397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance.
    Lloyd AA; Gludovatz B; Riedel C; Luengo EA; Saiyed R; Marty E; Lorich DG; Lane JM; Ritchie RO; Busse B; Donnelly E
    Proc Natl Acad Sci U S A; 2017 Aug; 114(33):8722-8727. PubMed ID: 28760963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered distributions of bone tissue mineral and collagen properties in women with fragility fractures.
    Wang ZX; Lloyd AA; Burket JC; Gourion-Arsiquaud S; Donnelly E
    Bone; 2016 Mar; 84():237-244. PubMed ID: 26780445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, Using Korean National Sample Cohort.
    Won SH; Ahn S; Ji E; Park JW; Kim JK; Lee YK
    J Korean Med Sci; 2020 Jun; 35(25):e193. PubMed ID: 32597040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the bisphosphonate holiday: a preliminary FTIRI study.
    Boskey AL; Spevak L; Ma Y; Wang H; Bauer DC; Black DM; Schwartz AV
    Osteoporos Int; 2018 Mar; 29(3):699-705. PubMed ID: 29204959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur.
    Zanchetta MB; Diehl M; Buttazzoni M; Galich A; Silveira F; Bogado CE; Zanchetta JR
    J Bone Miner Res; 2014 Apr; 29(4):999-1004. PubMed ID: 24115250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial.
    Adachi JD; Lyles K; Boonen S; Colón-Emeric C; Hyldstrup L; Nordsletten L; Pieper C; Recknor C; Su G; Bucci-Rechtweg C; Magaziner J
    Calcif Tissue Int; 2011 Dec; 89(6):427-33. PubMed ID: 22038744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis.
    Meinen R; Galli-Lysak I; Villiger PM; Aeberli D
    BMC Musculoskelet Disord; 2016 Aug; 17():324. PubMed ID: 27491286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
    Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
    N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the Relationships Between Bone Tissue Composition, Compositional Heterogeneity, and Fragility Fracture: A Matched Case-Controlled FTIRI Study.
    Boskey AL; Donnelly E; Boskey E; Spevak L; Ma Y; Zhang W; Lappe J; Recker RR
    J Bone Miner Res; 2016 May; 31(5):1070-81. PubMed ID: 26636271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourier transform infrared imaging of femoral neck bone: reduced heterogeneity of mineral-to-matrix and carbonate-to-phosphate and more variable crystallinity in treatment-naive fracture cases compared with fracture-free controls.
    Gourion-Arsiquaud S; Lukashova L; Power J; Loveridge N; Reeve J; Boskey AL
    J Bone Miner Res; 2013 Jan; 28(1):150-61. PubMed ID: 22865771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortical Bone Material Strength Index and Bone Microarchitecture in Postmenopausal Women With Atypical Femoral Fractures.
    Popp KL; Caksa S; Martinez-Betancourt A; Yuan A; Tsai J; Yu EW; Bouxsein ML
    J Bone Miner Res; 2019 Jan; 34(1):75-82. PubMed ID: 30281863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
    Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
    Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.
    Boskey AL; Spevak L; Weinstein RS
    Osteoporos Int; 2009 May; 20(5):793-800. PubMed ID: 18769963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
    Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
    JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.
    Gourion-Arsiquaud S; Allen MR; Burr DB; Vashishth D; Tang SY; Boskey AL
    Bone; 2010 Mar; 46(3):666-72. PubMed ID: 19925895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lateral Cortical Thickening and Bone Heterogeneity of the Subtrochanteric Femur Measured With Quantitative CT as Indicators for Early Detection of Atypical Femoral Fractures in Long-Term Bisphosphonate Users.
    Lee SH; Lee YH; Suh JS
    AJR Am J Roentgenol; 2017 Oct; 209(4):867-873. PubMed ID: 28796551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures.
    Phillips HK; Harrison SJ; Akrawi H; Sidhom SA
    Injury; 2017 Jun; 48(6):1159-1164. PubMed ID: 28410753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial.
    Papapoulos S; Bone H; Cosman F; Dempster DW; McClung MR; Nakamura T; Restrepo JFM; Bouxsein ML; Cohn D; de Papp A; Massaad R; Santora A
    J Bone Miner Res; 2021 Jul; 36(7):1225-1234. PubMed ID: 33724542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.
    Park-Wyllie LY; Mamdani MM; Juurlink DN; Hawker GA; Gunraj N; Austin PC; Whelan DB; Weiler PJ; Laupacis A
    JAMA; 2011 Feb; 305(8):783-9. PubMed ID: 21343577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.